APP下载

LC-MS/MS法测定肿瘤患者恶性腹水中紫杉醇的含量

2020-07-09黄翠云张凤柳珂陈万生杨军

中国药房 2020年1期
关键词:紫杉醇

黄翠云 张凤 柳珂 陈万生 杨军

摘 要 目的:建立测定肿瘤患者恶性腹水中紫杉醇含量的方法。方法:采用液相色谱-质谱联用(LC-MS/MS)技术,以文多灵为内标,测定肿瘤患者给予紫杉醇后恶性腹水中紫杉醇的含量,色谱柱为Zorbax SB-C18,流动相为水溶液(含0.1%甲酸和10 mmol/L醋酸铵)-乙腈溶液(40 ∶ 60,V/V),流速为0.25 mL/min,柱温为30 ℃,进样量为5 μL,离子源为电喷雾离子源,检测模式为多重反应离子监测正离子模式,干燥气温度为350 ℃,干燥气流速为10 L/min,毛细管电压为4 000 V,紫杉醇和内标在正离子模式下质荷比(m/z)分别为876.5→308.0、457.3→188.1,碎片电压分别为250、150 V,碰撞电压分别为30、20 eV。结果:紫杉醇检测质量浓度的线性范围为25~2 500 ng/mL(r2=0.996 5,n=7);定量下限为25 ng/mL;日内、日间精密度试验的RSD为0.61%~3.62%(n=5、3);准确度为95.34%~98.76%(n=5、3);提取回收率的RSD为3.19%~3.72%(n=3);基质效应的CV为1.52%~2.93%(n=3);稳定性试验的RE均小于3%(n=3)。结论:该方法简便、准确,可用于测定肿瘤患者恶性腹水中紫杉醇的含量。

关键词 液相色谱-质谱联用;肿瘤患者;腹水;紫杉醇;含量测定

中图分类号 R969 文献标志码 A 文章编号 1001-0408(2020)01-0086-05

DOI 10.6039/j.issn.1001-0408.2020.01.15

ABSTRACT   OBJECTIVE: To establish a method for content determination of paclitaxel in malignant ascites of tumor patients. METHODS: LC-MS/MS method was adopted. Using vindoline as internal standard, the content of paclitaxel in ascites of tumor patients was determined. The separation was performed on Zorbax SB-C18 column with mobile phase consisted of aqueous solution (containing 0.1% formic acid and 10 mmol/L ammonium acetate)-acetonitrile (40 ∶ 60, V/V) at the flow rate of 0.25 mL/min. the column temperature was 30 ℃, and sample size was 5 μL. The ion source was electrospray ion source, and the detection mode was multiple ion monitoring positive ion mode. MS parameters were set as following as dry gas temperature 350 ℃,dry gas flow rate 10 L/min,capillary voltage 4 000 V. Quantitative determination was operated in the multiple reaction monitoring (MRM) mode,with the ion transitions m/z 876.5→308.0 for paclitaxel and m/z 457.3→188.1 for the internal standard. The fragment voltage/collision energy for paclitaxel and the internal standard were 250 V/30 eV, and 150 V/20 eV,respectively. RESULTS: The linear range of paclitaxel were 25-2 500 ng/mL (r2=0.996 5, n=7). The lowest limit of quantitation was 25 ng/mL. RSDs of inter-day and intra-day precision tests were 0.61%-3.62%(n=5, 3). Accuracies were 95.34%-98.76%(n=5, 3). RSDs of extraction recovery were 3.19%-3.72%(n=3). CV of matrix effect were 1.52%-2.93%(n=3). RE of stability tests were lower than 3% (n=3). CONCLUSIONS: The method is simple, accurate and suitable for the content determination of paclitaxel in malignant ascites of tumor patients.

KEYWORDS   LC-MS/MS; Tumor patient; Malignant ascites; Paclitaxel; Content determination

惡性肿瘤已经成为全球较大的公共卫生问题之一[1]。恶性腹水是由于恶性肿瘤病变引起腹腔脏壁层腹膜发生弥漫性病变而导致腹腔内液体异常增多的现象,是恶性肿瘤晚期常见的并发症,在40%~60%的恶性腹水中能找到脱落的恶性肿瘤细胞[2]。紫杉醇是具有抗癌活性的二萜生物碱类化合物,在过去的几十年里,紫杉醇广泛用于卵巢癌、乳腺癌、肺癌等多种肿瘤的治疗,以紫杉醇为基础的联合治疗是上述恶性肿瘤晚期腹水的主要治疗方案[3-4]。已有研究表明,全身化疗联合腹腔灌注化疗方案对于全身多器官转移的晚期胃癌患者,尤其是腹膜转移胃癌患者,能够使抗癌药物在腹腔内维持较高的血药浓度,从而抑制肿瘤细胞生长[5]。……

登录APP查看全文

猜你喜欢

紫杉醇
电压门控离子通道参与紫杉醇所致周围神经病变的研究进展
心肌缺血预适应在紫杉醇释放冠脉球囊导管扩张术中的应用
MUC1靶向性载紫杉醇超声造影剂的制备及体外靶向实验
雷公藤内酯醇联合多西紫杉醇对PC-3/MDR细胞耐药的体外逆转作用
紫杉醇脂质体与紫杉醇不同途径灌注治疗兔舌癌的疗效研究
脂质体紫杉醇周疗方案与普通紫杉醇治疗乳腺癌的疗效及不良反应比较
护理干预对预防紫杉醇过敏反应疗效观察
紫杉醇C13侧链的硒代合成及其结构性质
替吉奥联合紫杉醇治疗晚期胃癌的疗效分析
紫杉醇新剂型的研究进展